Multiple Myeloma
Conditions
Keywords
MYELOMA, THALIDOMIDE, DEFIBRODITE
Brief summary
This study will evaluate the safety and the efficacy of the association of Melphalan/ Prednisone/Thalidomide/Defibrotide (MPTD) as salvage treatment in advanced and refractory myeloma patients. This association might further increase the response rate achieved by oral MPT regimen
Detailed description
Defibrotide (DF) is a novel orally bioavailable polydisperse oligonucleotide with anti-thrombotic and anti-adhesive effects, which has been shown to be active in various microangiopathies, including the treatment and prophylaxis of veno-occlusive disease. While DF has minimal inhibitory effect on multiple myeloma (MM) in cell isolates, it showed single agent activity on human MM xenografts in SCID/NOD mice and markedly increased responsiveness of MM to cytotoxic agents, including melphalan, cyclophosphamide and dexamethasone in the same models. DF might thus enhance the response rate of Melphalan, Prednisone and Thalidomide, while protecting against the prothrombotic state seen with this combination in the treatment of MM. In this multicenter, open label, non-randomised phase I/II trial, dosing safety and efficacy of melphalan, prednisone, thalidomide, and DF (MPTD) were determined in pts with relapsed/refractory MM. Primary refractory or pts receiving therapeutic anticoagulation were excluded. Oral melphalan was administered at 0,25 mg/Kg on D1-4, oral prednisone at 1,5 mg/kg on D 1-4, thalidomide was delivered at 50 mg on D1-35 on cycle 1 and at 100 mg from cycle 2 to cycle 6. Level + 1 DF = 17 mg/Kg i.v. or 2.4 g p.o. D1-4, followed by 1.6 g p.o. through D 35 Level + 2 DF = 34 mg/Kg i.v. or 4.8 g p.o. D 1-4, followed by 3.2 g p.o. through D 35 Level + 3 DF = 51 mg/Kg i.v. or 7.2 g p.o. D 1-4, followed by 4.8 g p.o. through D 35. Each course was repeated every 35d for a total of 6 courses and no DVT prophylaxis was used.
Interventions
DRUGPrednisone
Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)
DRUGMelphalan
Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
DRUGThalidomide
Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.
DRUGDefibrotide
Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
Sponsors
Silvio Aime
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Each patient must meet all of the following inclusion criteria to be enrolled in the study: * Patient is of a legally consenting age as defined by local regulations. * Patient is, in the investigator(s) opinion willing and able to comply with the protocol requirements. * Patient has given voluntary written informed consent before performance of any study-related procedure not part of normal medical care, with the understanding that consent may be withdrawn by the patient at any time without prejudice to their future medical care. * Female patient is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intrauterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. * Male patient agrees to use an acceptable method for contraception (i.e., condom or abstinence) for the duration of the study. * Patient was previously diagnosed with multiple myeloma based on standard criteria (see Section 13.2). * Patient is relapsed after one line of treatment but less than three lines, including high-dose chemotherapy with stem cell support, conventional poli-chemotherapy, thalidomide- and melphalan-based regimens * Patient with primary refractory disease will be considered not eligible * Patient has measurable disease, defined as follows: any quantifiable serum monoclonal protein value (generally, but not necessarily, greater than 1 g/dL of IgG M-Protein and greater than 0.5 g/dL of IgA M-Protein) and, where applicable, urine light-chain excretion of \>200 mg/24 hours. * Patient has a Karnofsky performance status ≥60%. * Patient has a life-expectancy \>3 months. * Patient has the following laboratory values within 14 days before Baseline (day 1 of the Cycle 1, before study drug administration): * Platelet count ≥90 x 109/L without transfusion support within 7 days before the test. * Absolute neutrophil count (ANC) ≥ 1.00 x 109/L without the use of growth factors * Corrected serum calcium ≤14 mg/dL (3.5 mmol/L). * Aspartate transaminase (AST): ≤ 2.5 x the upper limit of normal (ULN). * Alanine transaminase (AST): ≤ 2.5 x the ULN. * Total bilirubin: ≤ 1.5 x the ULN. * Calculated or measured creatinine clearance: ≥20 mL/minute
Exclusion criteria
Patients meeting any of the following
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The safety will be assessed by showing DLT and maximum tolerated dose (MTD) of defibrotide when administered in combination with MPT | 7 months | The DLT is defined by the development of febrile neutropenia, or Grade 4 neutropenia \>= a week, or Grade 4 hematologic toxicity except neutropenia, or any \>= Grade 3 non-hematologic toxicity considered by investigators to be related to study drug(s) in \>30% of pts. MTD: maximum tolerated dose |
| The efficacy will be assessed by showing at least 55% of patients in a minimal response (MR) or at least 10 % of pts in near complete remission (nCR). | 7 months | — |
Secondary
| Measure | Time frame |
|---|---|
| prolongation of progression-free survival | it will be evaluated from the date of enrolling until the date of first documented evidence of the end point. |
| duration of progression-free survival | it will be evaluated from the date of enrolling until the date of first documented evidence of the end point. |
| prolongs overall survival | it will be evaluated from the date of enrolling until the date of first documented evidence of the end point. |
Countries
Italy
Outcome results
None listed